Search Results - "Heerspink, HJ Lambers"

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers by Schievink, Bauke, de Zeeuw, Dick, Smink, Paul A, Andress, Dennis, Brennan, John J, Coll, Blai, Correa-Rotter, Ricardo, Hou, Fan Fan, Kohan, Donald, Kitzman, Dalane W, Makino, Hirofumi, Parving, Hans-Henrik, Perkovic, Vlado, Remuzzi, Giuseppe, Tobe, Sheldon, Toto, Robert, Hoekman, Jarno, Lambers Heerspink, Hiddo J

“…Background A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical…”
Get full text

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes by Savonitto, Stefano, Morici, Nuccia, Nozza, Anna, Cosentino, Francesco, Perrone Filardi, Pasquale, Murena, Ernesto, Morocutti, Giorgio, Ferri, Marco, Cavallini, Claudio, Eijkemans, Marinus Jc, Stähli, Barbara E, Schrieks, Ilse C, Toyama, Tadashi, Lambers Heerspink, H J, Malmberg, Klas, Schwartz, Gregory G, Lincoff, A Michael, Ryden, Lars, Tardif, Jean Claude, Grobbee, Diederick E

“…To define the predictors of long-term mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. A total of 7226 patients from a…”
Get more information

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop by Romero, Klaus, Sinha, Vikram, Allerheiligen, Sandra, Danhof, Meindert, Pinheiro, Jose, Kruhlak, Naomi, Wang, Yaning, Wang, Sue-Jane, Sauer, John-Michael, Marier, J. F., Corrigan, Brian, Rogers, James, Lambers Heerspink, H. J., Gumbo, Tawanda, Vis, Peter, Watkins, Paul, Morrison, Tina, Gillespie, William, Gordon, Mark Forrest, Stephenson, Diane, Hanna, Debra, Pfister, Marc, Lalonde, Richard, Colatsky, Thomas

“…Medical-product development has become increasingly challenging and resource-intensive. In 2004, the Food and Drug Administration (FDA) described critical…”
Get full text

Dual RAS therapy not on target, but fully alive by Lambers Heerspink, H J, de Zeeuw, D

“…Inhibitors of the renin-angiotensin system (RAS) form a cornerstone in the treatment of kidney disease. These drugs lower blood pressure and albuminuria, and…”
Get more information

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers by Smink, PA, Hoekman, J, Grobbee, DE, Eijkemans, MJC, Parving, H-H, Persson, F, Ibsen, H, Lindholm, L, Wachtell, K, de Zeeuw, D, Heerspink, HJ Lambers

“…Introduction We recently developed and validated in existing trials a novel algorithm (PRE score) to predict long-term drug efficacy based on short-term…”
Get full text